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It has been postulated that monitoring measurable residual disease(MRD) could be used as a surrogate marker of progression-free survival(PFS) in chronic lymphocytic leukemia (CLL) patients after treatment
with immunochemotherapy regimens. In this study, we analyzed the out-
come of 84 patients at 3 years of follow-up after first-line treatment with
fludarabine, cyclophosphamide and rituximab (FCR) induction followed by
36 months of rituximab maintenance thearpy. MRD was assessed by a
quantitative four-color flow cytometry panel with a sensitivity level of 10-4.
Eighty out of 84 evaluable patients (95.2%) achieved at least a partial
response or better at the end of induction. After clinical evaluation, 74
patients went into rituximab maintenance and the primary endpoint was
assessed in the final analysis at 3 years of follow-up. Bone marrow (BM)
MRD analysis was performed after the last planned induction course and
every 6 months in cases with detectable residual disease during the 36
months of maintenance therapy. Thirty-seven patients (44%) did not have
detectable residual disease in the BM prior to maintenance therapy.
Interestingly, 29 patients with detectable residual disease in the BM after
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Introduction
Chronic lymphocytic leukemia (CLL) is a mature B-cell
neoplasm characterized by a clonal proliferation and com-
partmentalized accumulation of neoplastic B cells within
the blood, bone marrow and secondary lymphatic organs.
The neoplastic B cells typically co-express CD5, and
CD19, CD20, and CD23; compared with normal B cells,
the levels of CD20 and CD79b on CLL cells are usually
diminished.1-4 Mutations of immunoglobulin heavy vari-
able chain (IGHV) genes and chromosomal abnormalities
are the most important predictors of disease course.
For physically fit patients requiring treatment according
to the International Workshop on CLL criteria, the combi-
nation of fludarabine, cyclophosphamide and the chimeric
anti-CD20 antibody rituximab (FCR) is the standard of
care for first-line treatment, based on the improvement of
progression-free survival (PFS) and overall survival (OS) of
patients treated with this combination compared with
those treated with combination chemotherapy alone.5
Following the introduction of purine analogs as a treat-
ment option, higher response rates and a higher propor-
tion of complete remissions were observed, and even bet-
ter outcomes have been reported in patients carrying
mutated IGHV genes (excluding 11q or 17p deletions);
patients treated with combination therapies such as FCR
may achieve a life expectancy close to that observed in the
matched normal general population.6-8
Achieving higher CR rates with chemoimmunotherapy
has translated into a documented increase in PFS and
seems to lead to an OS benefit, as shown in the CLL8 trial,
which reported a 33% reduced risk of death (P=0.01) with
the FCR regimen when compared to fludarabine plus
cyclophosphamide as first-line therapy. However, while
attainment of a CR has historically been considered the
gold-standard for treatment response, many of these
patients have persistent disease that cannot be easily iden-
tified by routine testing approaches.9 This, coupled with
the development of extremely sensitive testing technolo-
gies, has led to the emergence of measurable residual dis-
ease (MRD) as an important endpoint in the treatment of
CLL, especially in the era of chemoimmunotherapy.
Indeed, achieving undetectable MRD after chemoim-
munotherapy is a desirable goal, as MRD below a thresh-
old of 10-4 (0.01%) results in improvement of PFS and OS.8
We hypothesized that using MRD as a surrogate of treat-
ment effectiveness would allow determination of the effi-
cacy of new treatments without the need for prolonged
observation.
Several studies have shown that sequential use of induc-
tion/maintenance treatment can improve the quality of
response achieved with induction. Abrisqueta et al. recent-
ly reported an analysis of whether maintenance therapy
can improve the response achieved with induction
chemotherapy.10 Sixty-seven patients responding to induc-
tion therapy with FCR plus mitoxantrone (R-FCM)
received rituximab maintenance therapy (375 mg/m2)
every 3 months for 2 years. Approximately 40.6% of
patients achieved a CR with undetectable MRD at the end
of the maintenance treatment. It is important to note that
21% of the patients who had detectable MRD at the end
of R-FCM induction had an improved response after ritux-
imab maintenance therapy. Another study showed that
after responding to a fludarabine induction, patients who
had detectable MRD and were consolidated with four
monthly cycles of rituximab followed by a maintenance
regimen of 12 monthly rituximab doses had significantly
longer responses,compared to those who did not receive
consolidation (5-year OS: 87% vs. 32%; P<0.001). The
estimated 5-year PFS after induction was 73%.11
However, despite the improvements achieved with rit-
uximab maintenance therapy, there are some biological
features which confer a poor response to consolidation
plus maintenance therapy. Dal Bo et al. showed that
patients harboring the NOTCH1 mutation had a signifi-
cantly shorter OS compared with those with unmutated
NOTCH1. The independent prognostic impact of
NOTCH1 mutation on OS was confirmed in multivariate
analysis.12
In the light of these observations, we conducted a mul-
ticenter, non-randomized phase II clinical trial that aimed
to evaluate the efficacy, in terms of CR rate, of FCR as
induction no longer had detectable disease in the BM following maintenance therapy. After a median follow-
up of 6.30 years, the median overall survival (OS) and PFS had not been reached in patients with either unde-
tectable or detectable residual disease in the BM, who had achieved a complete response at the time of start-
ing maintenance therapy. Interestingly, univariate analysis showed that after rituximab maintenance OS was
not affected by IGHV status (mutated vs. unmutated OS: 85.7% alive at 7.2 years vs. 79.6% alive at 7.3 years,
respectively). As per protocol, 15 patients (17.8%), who achieved a complete response and undetectable
peripheral blood and BM residual disease after four courses of induction, were allowed to stop fludarabine
and cyclophosphamide and complete two additional courses of rituximab and continue with maintenance
therapy for 18 cycles. Surprisingly, the outcome in this population was similar to that observed in patients
who received the full six cycles of the induction regimen. These data show that, compared to historic con-
trols, patients treated with FCR followed by rituximab maintenance have high-quality responses with fewer
relapses and improved OS. The tolerability of this regime is favorable. Furthermore, attaining an early unde-
tectable residual disease status could shorten the duration of chemoimmunotherapy, reducing toxicities and
preventing long-term side effects. The analysis of BM MRD after fludarabine-based induction could be a
powerful predictor of post-maintenance outcomes in patients with CLL undergoing rituximab maintenance
and could be a valuable tool to identify patients at high risk of relapse, influencing further treatment strate-
gies. This trial is registered with EudraCT n. 2007-002733-36 and ClinicalTrials.gov Identifier:
NCT00545714.
first-line treatment for CLL, and to investigate the impact
of rituximab maintenance therapy on the response rate
and PFS following FCR. A key secondary objective was to
analyze MRD status after chemoimmunotherapy and rit-
uximab maintenance.
Methods
Physically fit patients between 18 and 70 years old with active
CD20+ CLL according to the World Health Organization classifi-
cation, with an Eastern Cooperative Oncology Group
Performance Status ≤2, were recruited into the REM (rituximab in
maintenance) trial and received treatment with fludarabine (25
mg/m2 iv on days 1-3), cyclophosphamide (250 mg/m2 iv on days
1-3) and rituximab (375 mg/m2 iv cycle 1 and 500 mg/m2 iv cycles
2-6) every 28 days, for up to six cycles. Major exclusion criteria
were prior treatment for CLL, severe cardiac, pulmonary, neuro-
logical, psychiatric, or metabolic disease, continuous systemic cor-
ticosteroids, active autoimmune hemolytic anemia or thrombocy-
topenia, active severe infection, creatinine clearance <50 mL/min,
or transformation to an aggressive B-cell malignancy. All cases
were CD20+ as analyzed by flow cytometry, with a mean fluores-
cence intensity lower than the expression found in normal mature
B lymphocytes in peripheral blood and bone marrow (BM).
At the 3-month post-induction clinical response evaluation,
patients achieving a CR, partial  response (PR) or nodular PR (nPR),
based on International Workshop on CLL guidelines, were treated
with rituximab 375 mg/m2 iv every 2 months for 3 years (18
cycles). Anti-microbial prophylaxis included trimethoprim-sul-
famethoxazole and acyclovir during treatment and until the level
of CD4+ lymphocytes reached 0.3x109/L. Patients achieving a CR
and undetectable MRD in both peripheral blood and BM after four
courses of FCR were allowed to stop fludarabine plus cyclophos-
phamide and complete two courses of rituximab and continue
with rituximab maintenance therapy.
The primary endpoint was the CR rate after FCR treatment.
Secondary endpoints included PFS, OS, correlation of response
with the level of MRD after FCR and rituximab maintenance ther-
apy, adverse events, and the prognostic impact of the biological
markers CD38 and ZAP70, IGHV mutational status, cytogenetic
abnormalities and BM-MRD on the course of the disease.
Fluorescence in situ hybridization and IGHV analysis were per-
formed locally in accredited laboratories using standardized proce-
dures.
The study protocol was approved by the institutional review
board of each participating institution and complied with the
Declaration of Helsinki, and existing Good Clinical Practice guide-
lines, laws and regulations. All participants provided written
informed consent before enrollment.
Flow cytometry and measurable residual disease analysis
Samples were stained and lysed using a direct immunofluores-
cence technique as previously described.13 The following antibody
combinations were used: (i) CD22/CD23/CD19/CD5; (ii)
FMC7/CD43/CD19/CD5; (iii) CD103/CD25/CD19/CD5; (iv)
CD10/CD11c/CD19/CD5; (v) CD20/CD38/CD19/CD5; (vi)
CD81/CD22/CD19/CD5; (vii) CD20/CD49d/CD19/CD5; (viii)
sIgk/sIgl/CD19/CD5, and (ix) ZAP70/CD3+CD56/CD19/CD5.
All monoclonal antibodies except ZAP70 were provided by
Becton Dickinson (San José, CA, USA). ZAP70 was purchased
from Immunotech (Marseille, France). Samples were acquired in a
FACSCalibur flow cytometer (Becton Dickinson) and analyzed
using Paint-A-Gate PRO software (Becton Dickinson). At least
20,000 events were acquired. B-lymphocytes were identified
according to their SSC/CD19+ distribution and the total percent-
age of pathological CD38 and CD49d B cells was reported. ZAP70
was quantified using a cut-off of ≥20% to define the ZAP70+ sub-
set of B cells.14
MRD was analyzed in samples from peripheral blood and BM
after induction and from BM during rituximab maintenance ther-
apy, with a combination of monoclonal antibodies slightly modi-
fied from that in the European Research Initiative on CLL (ERIC)
protocol: (i) CD20/CD38/CD19/CD5; (ii)
CD81/CD22/CD19/CD5; (iii) sIgL/sIgK/CD19/CD5; and (iv)
CD22/CD79b/CD19/CD5. CD43 was not included in the analy-
sis: we included the last combination instead of
CD43/CD79b/CD19/CD5 based on our previous experience with
that combination in the analysis of MRD in CLL.13 The minimum
number of pathological B cells acquired was that in the ERIC rec-
ommendations.15 To achieve a limit of detection of 0.01%, at least
200,000 events were acquired if the minimum population size was
20 and 500,000 events if the minimum population size was 50. We
prepared the necessary number of tubes for each combination to
acquire at least 200,000 events. The complete gating strategy is
described in the Online Supplement.
Statistical analysis
This was a two-staged, Simon optimal phase II clinical trial.
Based on a CR rate observed in previous trials of first-line therapy
ranging around 30%, the inactivity cut-off was chosen to equal
30% and the activity cut-off at least 50%. Hence, the hypotheses
of interest were H0: r≤0.3 against Ha: r≥0.5%, where r is the CR
rate. Using a type I error rate (α, probability of accepting an insuf-
ficiently active treatment, a false positive outcome) set at 0.05, and
a type II error rate (β, probability of rejecting an active treatment,
a false negative outcome) set at 0.20, we estimated that 90 patients
should be enrolled into this trial, assuming a 10% loss.
A descriptive analysis of continuous and qualitative variables
was performed. PFS, OS and duration of response were summa-
rized descriptively and graphically using the Kaplan and Meier
method in the overall population and separately by biological fac-
tors, genetic profiles and MRD status. The log-rank test was used
for comparisons of PFS and OS curves. The χ2 test was used to
assess the frequencies and differences of biological and cytogenet-
ic abnormalities. The relationship between these abnormalities
and MRD level was analyzed using logistic regression models.
Safety data were summarized for all treated patients during induc-
tion, maintenance and combined. All hypothesis tests were two-
sided and a P-value <0.05 was considered statistically significant.
All statistical computations were carried out with SPSS version
14.0 or subsequent versions.
Results
We present the results of an end-of-study analysis at 3
years of follow-up after 36 months of rituximab mainte-
nance therapy following FCR induction. Between October
2007 and December 2012, 90 patients were assessed for
eligibility in 29 center across Spain, and 84 were assigned
to FCR (6 patients did not meet the eligibility criteria, of
whom 2 after 1 treatment infusion) and were evaluable for
response in an intent-to-treat analysis (Figure 1). Overall,
79.8% (n=67) of the enrolled patients were aged 64 years
or younger, 67.9% (n=57) were male and 83.3% (n=70)
had Binet stage B or C disease. The median age of trial par-
ticipants was 59.5 years (range, 37-70), and 70.5% (n=55)
of participants were in a good state of health with an
Eastern Cooperative Oncology Group Performance Status
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of 0-1. Overall, 53.7% (n=45) of the trial population had B
symptoms.
Table 1 summarizes the biological and genetic abnor-
malities assessed at baseline that were considered to be
prognostic for outcome. Overall, 57.14% (n=48) of
patients had unmutated IGHV, 47.6% (n=39) were CD38+
and 57.3% (n=43) were ZAP70+. Forty-two (50.0%)
patients had a 13q14 deletion, 22 (26.1%) had a 11q22-q23
deletion, 13 (15.4%) harbored trisomy 12, four (4.7%)
patients had a 17p deletion, and three (3.5%) had a 6q
deletion.
Overall, 12 patients (14%) ended treatment induction
prematurely. The reasons for discontinuation included
toxicity (n=6), progressive disease (n=1), ineligibility
(n=2), and investigators’ decision (n=3: 1 patient with
ischemic cerebrovascular disease, 1 patient with concomi-
tant idiopathic thrombocytopenic purpura and 1 patient
with a karyotype with chromosomal random losses). The
median number of FCR cycles was six, and complete
treatment was administered to 80% of the patients.
Response and treatment outcomes
Induction 
Of 84 evaluable patients in an intent-to-treat analysis of
the effects of FCR induction treatment, 80 patients had a
CR/CR with incomplete hematologic recovery (CRi), PR
or nPR for an overall response rate of 95.2% (75.0%
CR/CRi(2), n=63; 7.1% nPR, n=6; 13.1% PR, n=11) while
four patients failed to respond to FCR. Of the 80 patients
evaluable for BM-MRD status, 44.1% (n=37) had unde-
tectable MRD at 3 months after induction, of whom 35
(41.7%) had a CR and two (2.4%) had a PR, while 43 had
detectable MRD, of whom 28 (35.0%) had a CR, eight
(10.0%) had a nPR, and seven (8.8%) had a PR.
Rituximab maintenance
Of the 80 patients with CR or PR after FCR induction,
74 entered the maintenance study. At the end of the main-
tenance phase, 52 patients had a CR and seven had a PR
(2 nPR; 5 PR). At cycle 12 of treatment, 29 patients had a
CR and four patients had attained a PR. At cycle 9, 42
patients had a CR and five had a PR. Reasons for discon-
J.A. García-Marco et al.
2252 haematologica | 2019; 104(11)
Figure 1. Consolidated Standards of
Reporting Trials (CONSORT) diagram. ITT:
intention-to-treat.
Table 1. Patients’ baseline characteristics.
Patients’ characteristics
Median age (range)                                                 59.5 years (37,1-70,9)
Sex (n; %)
Men                                                                                       57 (67.9)
Women                                                                                 27 (32.1)
ECOG performance status (n; %)
PS-0                                                                                       55 (70.5)
PS-≥1                                                                                    23 (29.4)
Binet stage (n; %)
A                                                                                             14 (16.7)
B                                                                                             53 (63.1)
C                                                                                             17 (20.2)
FISH cytogenetic status (n; %)
del(13q)                                                                               42 (50.0)
del(11q)                                                                               22 (26.1)
trisomy 12                                                                            13 (15.4)
del(17p)                                                                                 4 (4.7)
del(6q)                                                                                   3 (3.5)
IGHV status (n; %)
unmutated                                                                           48 (57.1)
IGHV 3-21                                                                               3 (3.6)
mutated                                                                                27 (32.1)
inconclusive                                                                          6 (7.1)
Immunophenotyping (n; %).
>10% CD38 positive                                                          53 (64,6)
>30% CD38 positive                                                          39 (47,6)
>20% ZAP70 positive                                                         43 (57,3)
>20% CD49d positive                                                        30 (37,0)
Response (n; %)
Complete response                                                          63 (75.0)
Partial response                                                                 11 (13.1)
Nodular partial response                                                  6 (7.1)
Undetectable MRD status post-induction
Peripheral blood                                                                60 (71.4)
Bone marrow                                                                      37 (44.0)
ECOG: Eastern Cooperative Oncology Group; PS: Performance Status; FISH: fluores-
cence in-situ hybridization; MRD; measurable residual disease.
tinuation were myelotoxicity (n=14; 18.9%), clinical pro-
gression (n=8; 10.8%), consent withdrawal (n=3; 4.0%)
investigator’s decision (n=1; 1.3%), protocol violation
(n=1; 1.3%), infection (n=3; 4.0%) and death (n=2; 2.7%).
During the follow-up period, all patients who were ana-
lyzed maintained CR or PR.
At the end of maintenance therapy, MRD assessed at
cycles 9, 12, 15 and 18 was negative in 44 of the 72
patients (61.1%) evaluable for response. Interestingly, 29
patients who had detectable BM-MRD immediately after
induction converted to an undetectable BM-MRD status
following rituximab maintenance therapy. In detail, after
nine cycles, 13 patients with detectable BM-MRD con-
verted to having undetectable BM-MRD and two with
undetectable BM-MRD became MRD-positive. After 18
cycles, 16 patients with detectable BM-MRD converted to
being MRD-negative and five with undetectable BM-
MRD became BM-MRD-positive (2 CR relapsed after 18
months, 1 CR interrupted treatment at 12 months because
of toxicity, 1 PR progressed after 13 months and 1 CR
relapsed after 4 months) (Table 2).
Survival 
At the end of the study, with a median follow-up of 6.3
years, the estimated proportions of patients who were
alive and progression-free were 0.76 and 0.61, respective-
ly. Analyzed according to their MRD status, patients with
a CR and either undetectable or detectable MRD did not
reach the median PFS and OS, while for patients with
detectable MRD and a PR the median PFS was 2.04 years
(95% CI: 0-4.3 years) and the median OS was 4.60 years
(95% CI: 3.0-6.1 years). Regarding response duration, a
total of 56 patients (71.2%) maintained their response
throughout the whole study: the median response dura-
tion was 6.4 years (95%CI: 6.08-6.68). Univariate Cox
regression analysis showed that IGHV status affected PFS:
the PFS rate at 7.3 years in patients with mutated IGHV
was 0.85, whereas it was 0.39 in those with unmutated
IGHV. However, the median OS for patients with either
mutated or unmutated IGHV was not reached (Figure 1).
No correlations were identified between the other clinical,
biological or molecular factors and the achievement of
undetectable MRD.
When MRD values were categorized into low (<0.01%,
i.e. less than 1 CLL cell per 10,000 leukocytes), intermedi-
ate (0.01% to 1%) and high (>1%), the median PFS and
OS were not reached in patients with low and intermedi-
ate MRD levels and were 2.0 years (95% CI: 0-4.3) and 4.6
years (95% CI: 4.2-4.9), respectively, in patients with high
MRD levels (Figure 2, and Table 3A and 3B).
Safety 
As per protocol, 86 patients were evaluated for safety
after FCR induction. The most common adverse events
were grade 1-2 rituximab infusion reactions (65.1%),
grade 3-4 myelosuppression (29 patients, 33.7%) and
infections (grade 1-2: 30 patients, 34.9%;  grade 3-4: 3
patients, 3.5%). In addition, there were 11 (12.8%) grade
Rituximab maintenance therapy in CLL 
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Figure 2. Progression-free survival and overall survival according to IGHV mutational status. PFS: progression-free survival; OS: overall survival.
Table 2. Measurable residual disease assessment.
MRD status                Induction (n=74)              6 Rm cycles (1 year) (n= 56)   12 Rm cycles (2 years) (n= 35)           18 Rm cycles (3 years) (n= 42)
Negative                                      33                                                         36                                                         23                                                                     31
Positive                                        41                                                         20                                                         12                                                                     11
MRD: measurable residual disease; Rm: rituximab maintenance therapy.
3-4 non-hematologic serious adverse events. 
The most common adverse event during rituximab
maintenance therapy was grade 3-4 myelosuppression,
which occurred in 28 patients (37.8%). In more detail,
neutropenia between cycles and anemia were observed in
27 patients (36.5%) and one patient (1.4%), respectively.
Grade 1-2 infections were detected in 43 patients (58.1%),
while grade 3-4 infections were documented in ten
patients (13.5%) and were pneumonia (n=5), respiratory
tract infections (n=2), meningitis (n=1), viral myocarditis
(n=1), and gastroenteritis (n=1). Febrile neutropenia was
observed in five patients (6.8%).
Discussion
Despite the improved efficacy of currently approved
chemoimmunotherapy in CLL patients, the majority of
patients, including those who achieve CR, eventually
relapse as a consequence of residual malignant cells still
present after therapy. The high CR rate recorded in this
study indicates that FCR induction followed by rituximab
maintenance therapy produces a high overall response
rate in patients considered fit for fludarabine-based thera-
py. By increasing the quality of clinical responses through
obtaining a high undetectable MRD CR rate, the PFS of
patients with a clinical response is prolonged. Ultimately,
this confirms the role and value of undetectable MRD sta-
tus in CLL. 
In our study, MRD in BM was undetectable at the 10-4
level in 44% of the 80 patients evaluated after the induc-
tion treatment and in 68% of 59 patients at the end of
maintenance therapy. Furthermore, rituximab mainte-
nance therapy significantly increased the number of
patients with undetectable MRD in BM. Indeed, 40
patients with detectable BM-MRD converted to an unde-
tectable BM-MRD status from cycle 9 and subsequent
cycles. Additionally, although small numbers limited our
subgroup analysis, it is remarkable that 41%, 58% and
60% of patients with undetectable MRD following ritux-
imab maintenance therapy (n=40) harbored factors well-
known to be associated with lower response and poor
long-term outcomes.16-18 Our data suggest a PFS benefit
from rituximab maintenance therapy in IGHV-mutated vs.
unmutated patients (PFS at 7.2 year: 84.5% vs. 39.1%,
respectively). Overall, clinical outcomes were encouraging
in this study as the median OS and PFS were not reached.
The estimated 7-year PFS and OS rates were 56.2% and
78.0%, respectively. Of note, the median OS and PFS for
patients with a CR and either undetectable BM-MRD or
detectable BM-MRD were not reached. However, despite
these data suggesting a benefit on time-to-event curves, it
is important to note that this was not a randomized study.
Nevertheless, although direct comparisons between trials
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2254 haematologica | 2019; 104(11)
Table 3A. Progression-free and overall survival according to measura-
ble residual disease group assessment at the staging following treat-
ment with fludarabine, cyclophosphamide, and rituximab.
MRD Group             Low             Intermediate                   High
                            (<0.01%)          (0.01%-1%)                   (>1%)
PFS                                NR                          NR               2.0 years (95% CI: 0-4.3)
OS                                  NR                          NR               4.6 years (95% CI: 0-4.3)
MRD: measurable residual disease; PFS: progression-free survival; OS: overall survival;
NR: not reached; 95% CI: 95% confidence interval.
Table 3B. Seven-year progression-free and overall survival rates after
36 months of maintenance therapy according to measurable residual
disease group.
MRD Group             Low             Intermediate                   High
                            (<0.01%)          (0.01%-1%)                   (>1%)
PFS                              93.2%                      25.0%                             28.6 %
OS                                100%                       100%                              68.6%
MRD: measurable residual disease; PFS: progression-free survival; OS: overall survival.
Figure 3. Progression-free survival and overall survival according to measurable residual disease status. PFS: progression-free survival; OS: overall survival; MRD:
measurable residual disease; NR: not reached.
is not recommended, these results (along with published
data), suggest that maintenance treatment with a
chemotherapy-free approach would improve long-term
outcomes with acceptable toxicity. Furthermore, when
MRD values were categorized into low (<0.01%), inter-
mediate (0.01% to 1%) and high (>1%), low and interme-
diate MRD levels were associated with longer PFS and OS
following rituximab maintenance therapy (OS: P<0.0001)
compared with higher MRD levels which were associated
with significantly shorter PFS and OS (2.0 and 4.6 years,
respectively), suggesting a favorable prognostic effect of
MRD level for patients given rituximab maintenance ther-
apy.
The relationship between undetectable MRD following
frontline therapy and long-term outcomes, namely PFS
and OS, has been investigated extensively in recent years.
Nevertheless, to our knowledge, our study has one of the
longest maintenance phases given to CLL patients in first
remission. The German CLL Study Group (GCLLSG)
updated the CLL8 trial which compared FCR to fludara-
bine plus cyclophosphamide in untreated CLL patients.
With a median follow-up of 5.9 years, the median PFS for
the patients treated with FCR was 56.8 months, and the
median OS was not reached in the FCR group.5,6
Furthermore, patients achieving undetectable MRD had a
significantly longer PFS (64.0 months) while the median
OS was not reached. The rituximab-containing arm pro-
duced twice the number of patients achieving unde-
tectable MRD. 
In our study, median PFS and OS were not reached for
patients with undetectable BM-MRD. We hypothesized
that this difference was probably due to the source of
samples. These data suggest that higher response rates
and longer response durations could be expected by inten-
sifying therapy through prolonged maintenance treatment
with anti-CD20 immunotherapy.19 In addition, a com-
bined analysis of the CLL8 and CLL10 trials showed that
PFS was significantly longer in patients with undetectable
MRD than in those with detectable MRD, despite being
unaffected by the residual tumor load, thus supporting the
prognostic significance of undetectable MRD in CLL
patients.20 In another study Greil et al. enrolled patients
who had achieved a CR, CRi or PR after first- or second-
line rituximab-based chemoimmunotherapy.21 PFS was
significantly longer in the rituximab maintenance arm
(47.0 vs. 35.5 months, HR 0.50, 95% CI: 0.38-0.66;
P<0.0001), suggesting that remission maintenance is an
effective and safe option for CLL patients. In that study,
MRD progression was documented more frequently in
patients on observation than in those on rituximab main-
tenance therapy (P<0.0001) and, interestingly, conversion
to undetectable MRD status occurred more frequently in
the rituximab maintenance arm (12 patients vs. 1 patient;
P=0.003). Based on these data, it seems that maintenance
therapy may improve the quality of remission in CLL sub-
jects and prolong PFS.
Although firm conclusions are limited by the number of
subjects in our trial, patients who discontinued chemoim-
munotherapy after achieving undetectable BM-MRD CR
at cycle 4 and continued with the maintenance phase had
similar PFS and OS rates to those of patients who achieved
undetectable MRD but continued treatment for all six
cycles: 93.3% and 76.5% were alive at 7 years, while
80.0% and 60.6% were free of disease at 7 years, respec-
tively. In the light of these data, it might be useful to eval-
uate the efficacy and efficiency of a strategy that adapts
the duration of treatment to achieve undetectable MRD.
Although a high rate of falsely negative MRD in peripher-
al blood up to 12 months has been reported with ritux-
imab-containing regimens (20-30%), our hypothesis was
based on the predictive model published by Dimier et al.,
testing the effect of treatment on PFS using MRD as a sur-
rogate endpoint.22 Thus, we only stopped FCR after four
cycles when MRD was undetectable in both peripheral
blood and BM. Although MRD-tailored therapy has not
been validated prospectively, Strati et al. showed that
patients who discontinued frontline FCR after achieving
undetectable MRD after three cycles of treatment had
similar PFS and OS to those who achieved undetectable
MRD but continued treatment for all six cycles.23
Furthermore, PFS in the subgroup of patients who discon-
tinued frontline FCR after three cycles of treatment
because they had achieved undetectable MRD was better
than the PFS of patients who remained with detectable
MRD at the end of the course of six cycles, despite the
shorter duration of treatment in the former group. In addi-
tion, Thompson et al. recently reported that undetectable
MRD after course 3 of FCR predicted a greater likelihood
of undetectable MRD at the end of therapy.24
Although the study was designed before the ERIC rec-
ommended diagnostic markers were published, with a
median number of BM leukocytes of around 410,000
(range, 150,000-610,000) and a sensitivity of MRD detec-
tion of ≥10-4, the immunophenotypic CLL analysis per-
formed in this study was robust. The methodology for
assessing MRD was similar to the flow cytometry
methodology established by the ERIC consortium, as
three of the tubes were similar to the subsequently pub-
lished ERIC recommendations.15,25,26 The potential limita-
tion of the flow cytometry assay is the need for at least 106
cells per tube and a total of four tubes, which may be an
issue to keep in mind when small samples are available. In
addition, selection of the sample source remains a chal-
lenge, as a significant discrepancy between MRD status
determined in peripheral blood and BM has been report-
ed.27 A paired analysis of peripheral blood and BM samples
in our study revealed that 60 patients did not have
detectable MRD in peripheral blood, while only 37
achieved undetectable MRD in the BM. This discrepancy
is partially a result of the compartmental nature of CLL,
with disease reservoirs in the BM, blood, lymph nodes,
liver, and spleen. As rituximab targets CD20 on mature,
malignant and benign B cells, rituximab-based therapy
will achieve undetectable MRD much more rapidly in
peripheral blood than in BM. Indeed, in the REM trial we
decided to use the CD20 marker in two of our MRD tubes
for two reasons, (i) CD20 as a single marker provides the
most powerful separation of CLL cells from normal B
cells, and (ii) in patients treated with rituximab-containing
regimens, the correlation between real-time quantitative
polymerase chain reaction findings and the results of
assays with combinations including the CD20 marker was
not weaker than that with combinations not including the
CD20 marker.28
Based on the results described above, it appears that 3
years of rituximab maintenance therapy was beneficial for
enrolled patients, improving the quality of remissions and
prolonging survival. The reason for the high response
rates, undetectable MRD and favorable PFS and OS rates
compared to those from clinical trials with similar entry
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criteria is probably multifactorial, but may include the age
and Performance Status of the patients: their median age
was 59.5 years and up to 70.5% patients had an Eastern
Cooperative Oncology Group Performance Status of 0.
Additionally, the protocol-defined anti-microbial prophy-
laxis scheduled for this trial allowed a treatment compli-
ance of around 80%. Furthermore, the secondary end-
point of undetectable MRD is strongly associated with
outcome: at the post-maintenance assessment, 68% of
assessed patients had undetectable MRD. Finally, the
median follow-up of 75.6 months is long enough to allow
solid interpretation of both PFS and OS.
A weakness of this trial is that, since its design, new
drugs targeting signaling pathways, and newer monoclon-
al antibodies have become available, and the interest in
chemoimmunotherapy, such as FCR, has weakened.
Additionally, since OS findings have been inconsistent and
one could argue that prolonged maintenance use of certain
molecules could expose CLL patients to increased toxicity
and ultimately reduce their quality of life, the debate
should be whether to use rituximab for maintenance or to
watch and wait and give these therapies when the
patients relapse. Upon closer examination of our results,
patients with unfavorable cytogenetics, unmutated
somatic IGHV genes, and CD38 and ZAP70 expression
benefited from rituximab maintenance therapy. Further
research is now needed to identify subgroups of patients
who may benefit while on maintenance therapy.
Of the 957 treatment-emergent adverse events, 54%
occurred during induction treatment; most were classed as
neutropenia or lymphopenia, and almost half (47.4%)
were suspected to be related to rituximab. However, the
same adverse events could be related to more than one of
the drugs administered. The most frequent of the 440
treatment-emergent adverse events recorded during the
maintenance period was neutropenia, which was record-
ed in 43.3% of the patients. Of the total of 957 treatment-
emergent adverse events, 26.6% were assessed as grade
≥3 and the majority were associated with disorders in the
blood and lymphatic systems. Sixteen out of 20 deaths
reported in the study occurred during the maintenance
period. There was only one treatment-related death,
which happened during the maintenance period. Overall,
the safety profile of rituximab in the maintenance setting
was consistent with its expected safety profile and no new
unexpected adverse events were reported.
In summary, this study provides the first insights into
the potential clinical use of FCR treatment followed by a
3-year period of rituximab maintenance as a treatment
strategy. Our study suggests that maintenance therapy
with rituximab further prolongs responses in CLL
patients with detectable MRD (when judged against his-
torical outcomes after FCR treatment), with significantly
improved PFS and OS for patients who achieved at least
a PR after FCR induction. Based on these results, unde-
tectable MRD is confirmed as a predictive biomarker
associated with treatment response following rituximab
maintenance therapy. Prospective studies aimed at evalu-
ating long-term outcomes following early treatment dis-
continuation and the potential benefit in terms of reduc-
ing acute and delayed toxicity are necessary before MRD
testing can be used to guide treatment decisions in clinical
practice.
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